JP2014526469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526469A5 JP2014526469A5 JP2014529913A JP2014529913A JP2014526469A5 JP 2014526469 A5 JP2014526469 A5 JP 2014526469A5 JP 2014529913 A JP2014529913 A JP 2014529913A JP 2014529913 A JP2014529913 A JP 2014529913A JP 2014526469 A5 JP2014526469 A5 JP 2014526469A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- unsubstituted
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
- 230000009529 traumatic brain injury Effects 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 208000029560 autism spectrum disease Diseases 0.000 claims description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 229940127240 opiate Drugs 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 208000022821 personality disease Diseases 0.000 claims description 2
- 230000000698 schizophrenic effect Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000034 method Methods 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 0 C1C2(CCC*3)C33C2C1*3 Chemical compound C1C2(CCC*3)C33C2C1*3 0.000 description 3
- PYJAYEGNRABCLY-SVAFWTMJSA-N CC(C)(CCC(C)(C)O)[C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 Chemical compound CC(C)(CCC(C)(C)O)[C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 PYJAYEGNRABCLY-SVAFWTMJSA-N 0.000 description 1
- CEBHHEZNBBYQSM-KRGDYOPUSA-N CC(C)C(CC[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O Chemical compound CC(C)C(CC[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O CEBHHEZNBBYQSM-KRGDYOPUSA-N 0.000 description 1
- QLQYZOMZOGPIOC-QTFZZFSVSA-N CC(C)C(CO[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O Chemical compound CC(C)C(CO[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)=O QLQYZOMZOGPIOC-QTFZZFSVSA-N 0.000 description 1
- CKIKDYISGBHWPU-MHLXRUGDSA-N CC(CC(CO)(F)F)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CC(CO)(F)F)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 CKIKDYISGBHWPU-MHLXRUGDSA-N 0.000 description 1
- CHGDJFGOJYCPHZ-QQHYONEASA-N CC(CCC(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1 CHGDJFGOJYCPHZ-QQHYONEASA-N 0.000 description 1
- GUUYVPWCEUMENE-SHOUTUCRSA-N CC(CCC1(CC1)O)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCC1(CC1)O)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 GUUYVPWCEUMENE-SHOUTUCRSA-N 0.000 description 1
- PQNBSROBFNWPRX-XLUYLUSISA-N CC(CCCO)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 Chemical compound CC(CCCO)[C@@H](CC1)C(C)(CC2)C1C1C2C(CC[C@@H](C2)O)C2=CC1 PQNBSROBFNWPRX-XLUYLUSISA-N 0.000 description 1
- HBKQWULJDAALRY-NLIMMPQESA-N CC([C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1)C(CO)(F)F Chemical compound CC([C@@H](CC1)C(C)(CC2)C1C1C2[C@@H](CC[C@@H](C2)O)C2=CC1)C(CO)(F)F HBKQWULJDAALRY-NLIMMPQESA-N 0.000 description 1
- RVXHMRSBDNBDEY-UHFFFAOYSA-N CCOC(C(C)C)(F)F Chemical compound CCOC(C(C)C)(F)F RVXHMRSBDNBDEY-UHFFFAOYSA-N 0.000 description 1
- VOXRDLZRMKBAFE-UHFFFAOYSA-N CCO[IH][IH]CC(C)OCC(C)(F)F Chemical compound CCO[IH][IH]CC(C)OCC(C)(F)F VOXRDLZRMKBAFE-UHFFFAOYSA-N 0.000 description 1
- UIIQWGBQZPMASR-UHFFFAOYSA-N COCC(F)(F)I Chemical compound COCC(F)(F)I UIIQWGBQZPMASR-UHFFFAOYSA-N 0.000 description 1
- ZOOUPKHXFIPMMF-DYNRJKDWSA-N C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O ZOOUPKHXFIPMMF-DYNRJKDWSA-N 0.000 description 1
- XDYKAHLZXSUEFM-FQJGFYLYSA-N C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OCC(C(F)(F)F)=O Chemical compound C[C@@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OCC(C(F)(F)F)=O XDYKAHLZXSUEFM-FQJGFYLYSA-N 0.000 description 1
- RJXMOBXFLJYGMG-GRMHXZAGSA-N C[C@@](CC1)([C@@H](CCCC(O)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 Chemical compound C[C@@](CC1)([C@@H](CCCC(O)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 RJXMOBXFLJYGMG-GRMHXZAGSA-N 0.000 description 1
- HSPFXQHDOBRBLE-QRIWCCNGSA-N C[C@@](CC1)([C@@H](COCC(C(F)(F)F)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 Chemical compound C[C@@](CC1)([C@@H](COCC(C(F)(F)F)=O)CC2)C2C2C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC2 HSPFXQHDOBRBLE-QRIWCCNGSA-N 0.000 description 1
- LSWHPMWXDZERPR-IVFIPZGWSA-N C[C@H](CC(C(F)(F)F)=O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2C(C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC(C(F)(F)F)=O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2C(C)(CC[C@@](C)(C2)O)C2=CC1 LSWHPMWXDZERPR-IVFIPZGWSA-N 0.000 description 1
- BJHUPERNCXCFTH-JFBOSTTDSA-N C[C@H](CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CCC(C2)=O)C2=CC1 Chemical compound C[C@H](CCC(C)(C)O)[C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@H](CCC(C2)=O)C2=CC1 BJHUPERNCXCFTH-JFBOSTTDSA-N 0.000 description 1
- LLAUXVXYDZUXBL-VKHMYHEASA-N C[C@H](OC(C)(F)F)I Chemical compound C[C@H](OC(C)(F)F)I LLAUXVXYDZUXBL-VKHMYHEASA-N 0.000 description 1
- ZOOUPKHXFIPMMF-HZKWPTRHSA-N C[C@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O Chemical compound C[C@H]([C@@H](CC1)[C@@](C)(CC2)C1C1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(c1ccccc1)=O ZOOUPKHXFIPMMF-HZKWPTRHSA-N 0.000 description 1
- ZZLABZROPODDLV-DNCNGORPSA-N C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCC(C(F)(F)F)=O Chemical compound C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCC(C(F)(F)F)=O ZZLABZROPODDLV-DNCNGORPSA-N 0.000 description 1
- JLWWULDDVJQPID-HHZWQIATSA-N C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCCC(C(F)(F)F)=O Chemical compound C[C@](CC1)(C(CC2)C3C1[C@@](C)(CC[C@@](C)(C1)O)C1=CC3)[C@H]2OCCC(C(F)(F)F)=O JLWWULDDVJQPID-HHZWQIATSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532427P | 2011-09-08 | 2011-09-08 | |
| US61/532,427 | 2011-09-08 | ||
| PCT/US2012/054261 WO2013036835A1 (en) | 2011-09-08 | 2012-09-07 | Neuroactive steroids, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017169737A Division JP2018021059A (ja) | 2011-09-08 | 2017-09-04 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526469A JP2014526469A (ja) | 2014-10-06 |
| JP2014526469A5 true JP2014526469A5 (enExample) | 2015-10-29 |
| JP6205362B2 JP6205362B2 (ja) | 2017-09-27 |
Family
ID=46964032
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529913A Active JP6205362B2 (ja) | 2011-09-08 | 2012-09-07 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2017169737A Withdrawn JP2018021059A (ja) | 2011-09-08 | 2017-09-04 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2019011169A Active JP6777773B2 (ja) | 2011-09-08 | 2019-01-25 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2020170611A Withdrawn JP2021008504A (ja) | 2011-09-08 | 2020-10-08 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2023001738A Active JP7786665B2 (ja) | 2011-09-08 | 2023-01-10 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2025064398A Pending JP2025108535A (ja) | 2011-09-08 | 2025-04-09 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017169737A Withdrawn JP2018021059A (ja) | 2011-09-08 | 2017-09-04 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2019011169A Active JP6777773B2 (ja) | 2011-09-08 | 2019-01-25 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2020170611A Withdrawn JP2021008504A (ja) | 2011-09-08 | 2020-10-08 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2023001738A Active JP7786665B2 (ja) | 2011-09-08 | 2023-01-10 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| JP2025064398A Pending JP2025108535A (ja) | 2011-09-08 | 2025-04-09 | 神経刺激性のステロイド、組成物、およびそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US20150158903A1 (enExample) |
| EP (2) | EP4245369A3 (enExample) |
| JP (6) | JP6205362B2 (enExample) |
| CN (4) | CN113956315B (enExample) |
| AU (6) | AU2012304412A1 (enExample) |
| BR (1) | BR112014005373B1 (enExample) |
| CA (1) | CA2848212C (enExample) |
| DK (1) | DK2753632T3 (enExample) |
| ES (1) | ES2951664T3 (enExample) |
| FI (1) | FI2753632T3 (enExample) |
| HR (1) | HRP20230747T1 (enExample) |
| HU (1) | HUE062616T2 (enExample) |
| LT (1) | LT2753632T (enExample) |
| PL (1) | PL2753632T3 (enExample) |
| PT (1) | PT2753632T (enExample) |
| RS (1) | RS64332B1 (enExample) |
| RU (1) | RU2665571C2 (enExample) |
| SI (1) | SI2753632T1 (enExample) |
| SM (1) | SMT202300232T1 (enExample) |
| WO (1) | WO2013036835A1 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| KR101415329B1 (ko) | 2005-11-28 | 2014-07-04 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
| EP4245369A3 (en) * | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| AU2013212287B2 (en) | 2012-01-23 | 2017-11-23 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating CNS disorders |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| IL304912A (en) | 2012-08-21 | 2023-10-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| EP4335505A3 (en) | 2012-11-30 | 2024-06-05 | The Regents of The University of California | Anticonvulsant activity of steroids |
| MX362544B (es) * | 2013-03-13 | 2019-01-24 | Sage Therapeutics Inc | Esteroides neuroactivos y metodos para su uso. |
| EP3865135A3 (en) * | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids for use in therapy |
| TR201901745T4 (tr) * | 2013-04-17 | 2019-03-21 | Sage Therapeutics Inc | 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri. |
| WO2014169836A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| EP2986624B1 (en) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| RU2754534C2 (ru) | 2013-07-19 | 2021-09-03 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их использование |
| CA3235088A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| DK3086793T3 (da) | 2013-12-24 | 2022-08-01 | Univ Virginia Commonwealth | Anvendelse af oxygenerede cholesterolsulfater (ocs) til behandling af nyredysfunktion |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JP6628745B2 (ja) * | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| BR112017007053A2 (pt) * | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| TW202426002A (zh) | 2014-10-16 | 2024-07-01 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
| EP3753927B1 (en) | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3224269T (lt) | 2014-11-27 | 2020-07-10 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
| HUE054092T2 (hu) | 2015-01-26 | 2021-08-30 | Sage Therapeutics Inc | Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2017007832A1 (en) * | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| SI3812392T1 (sl) * | 2015-07-06 | 2025-09-30 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| MA42410B1 (fr) * | 2015-07-06 | 2021-04-30 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| MX2018001145A (es) * | 2015-07-30 | 2018-06-15 | Intercept Pharmaceuticals Inc | Métodos para la preparación de ácidos biliares y derivados de los mismos. |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| US9637514B1 (en) | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
| DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
| US20190047939A1 (en) * | 2016-03-02 | 2019-02-14 | Patheon Austria Gmbh & Co Kg | Process and intermediates for the production of 17(20)-ene b-seco steroids |
| HK1258616A1 (zh) * | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| HUE059491T2 (hu) * | 2016-04-01 | 2022-11-28 | Sage Therapeutics Inc | Oxiszterolok és azok alkalmazási eljárásai |
| WO2017193046A1 (en) * | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3481846T (pt) * | 2016-07-07 | 2021-08-13 | Sage Therapeutics Inc | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| DK3481845T3 (da) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder |
| MX2019001323A (es) | 2016-08-02 | 2019-07-04 | Univ Virginia Commonwealth | Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico. |
| EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| EP3519422B1 (en) * | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| MA46566A (fr) * | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| EP4105223B1 (en) * | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| LT3596041T (lt) | 2017-03-15 | 2023-01-25 | Modernatx, Inc. | Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| US11203569B2 (en) | 2017-03-15 | 2021-12-21 | Modernatx, Inc. | Crystal forms of amino lipids |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| CN109280069B (zh) * | 2017-07-19 | 2020-09-04 | 青岛海洋生物医药研究院股份有限公司 | 3β-羟基-麦角甾-5-烯甾类衍生物及其药物用途 |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| IT201700100483A1 (it) * | 2017-09-07 | 2019-03-07 | Dipharma Francis Srl | Ossidazione selettiva dell’acido iodesossicolico |
| AU2019314405A1 (en) * | 2018-07-31 | 2021-03-18 | Chisholm, John D. | Methods of activating microglial cells |
| JP2022501348A (ja) * | 2018-09-19 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | ステロール類似体及びその使用 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| BR112021013393A2 (pt) | 2019-01-08 | 2021-09-14 | Chengdu Kanghong Pharmaceutical Co, Ltd. | Composto de esteroide e uso do mesmo e método de preparação para o mesmo |
| CN114206900A (zh) | 2019-05-31 | 2022-03-18 | 萨奇治疗股份有限公司 | 神经活性类固醇及其组合物 |
| MX2021015942A (es) * | 2019-06-27 | 2022-04-18 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del snc. |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| BR112022004759A2 (pt) | 2019-09-19 | 2022-06-21 | Modernatx Inc | Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| KR20220134529A (ko) | 2019-12-06 | 2022-10-05 | 마리누스 파마슈티컬스 인코포레이티드 | 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론 |
| CN113387991B (zh) * | 2020-03-13 | 2024-06-18 | 苏州朗科生物技术股份有限公司 | 一种合成地屈孕酮的方法及化合物 |
| US20240239835A9 (en) * | 2020-03-18 | 2024-07-18 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CZ309819B6 (cs) * | 2020-10-23 | 2023-11-08 | Univerzita Palackého v Olomouci | Sterolové deriváty, přípravky obsahující tyto deriváty a jejich použití |
| CN112679571A (zh) * | 2020-12-24 | 2021-04-20 | 广西壮族自治区中国科学院广西植物研究所 | 一种罗汉果醇衍生物单体、其制备方法及应用 |
| CA3223179A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| JP2024534558A (ja) | 2021-09-22 | 2024-09-20 | セージ セラピューティクス， インコーポレイテッド | 重水素化ｎｍｄａ正調節化合物及びその使用方法 |
| KR102749670B1 (ko) * | 2021-09-28 | 2025-01-03 | 경희대학교 산학협력단 | 신규한 콜린산 유도체 및 이의 용도 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN115624555A (zh) * | 2022-02-24 | 2023-01-20 | 中国药科大学 | 猪去氧胆酸在制备抗抑郁药物中的应用 |
| US12454547B2 (en) | 2022-04-22 | 2025-10-28 | Asteroid Therapeutics | Steroidal compositions and methods of treating lipogenic cancers |
| TW202430133A (zh) * | 2022-11-21 | 2024-08-01 | 美商賽吉醫療公司 | 負ｎｍｄａ調節化合物及其使用方法 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) * | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) * | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| GB1120870A (en) | 1966-07-11 | 1968-07-24 | Ici Ltd | Quinoline derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| US4358406A (en) * | 1981-07-27 | 1982-11-09 | Wisconsin Alumni Research Foundation | 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS6253960A (ja) | 1985-05-30 | 1987-03-09 | Taisho Pharmaceut Co Ltd | ビタミンｄ↓３の誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| JPH03500049A (ja) * | 1987-08-25 | 1991-01-10 | ジー、ケルビン・ダブリュー | ストレス、不安および発作活性の緩和のための組成物および方法 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| KR100338287B1 (ko) | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) * | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| GEP20002033B (en) * | 1994-11-23 | 2000-04-10 | Cocensys Inc Us | Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor |
| JPH08268917A (ja) * | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| ES2235187T3 (es) * | 1995-06-06 | 2005-07-01 | Euro-Celtique S.A. | Esteroides neuroactivos de las series del androstano y el pregnano. |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| WO1997000884A1 (en) | 1995-06-23 | 1997-01-09 | Novo Nordisk A/S | Meiosis regulating compounds |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| EP1077933A1 (en) | 1998-05-11 | 2001-02-28 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| IL146230A0 (en) | 1999-04-29 | 2002-07-25 | Purdue Pharma Ltd | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| GB9910934D0 (en) * | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| WO2002090375A2 (en) | 2001-05-03 | 2002-11-14 | The University Of Chicago | Liver x receptor agonists |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1450816A4 (en) * | 2001-11-08 | 2008-02-13 | Univ Chicago | METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE |
| CA2468989A1 (en) | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
| WO2003082893A2 (en) | 2002-03-27 | 2003-10-09 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| WO2006050165A2 (en) | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| EA200802167A1 (ru) * | 2006-04-22 | 2009-04-28 | Холлис-Эден Фармасьютикалс, Инк. | Лекарства и применения |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) * | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| IN2014DN02014A (enExample) | 2006-11-21 | 2015-07-10 | Umecrine Ab | |
| KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논 |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059239A2 (en) * | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| JP2011502974A (ja) | 2007-11-06 | 2011-01-27 | ナームローゼ・フエンノートチヤツプ・オルガノン | ヒトにおけるホルモン抑制の方法 |
| US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| US8273737B2 (en) | 2008-01-25 | 2012-09-25 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| WO2010088414A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| US8829213B2 (en) | 2009-07-29 | 2014-09-09 | The University Of Chicago | Liver X receptor agonists |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| EP4245369A3 (en) | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| JP6542127B2 (ja) | 2012-12-18 | 2019-07-10 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法 |
| WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| MX362544B (es) | 2013-03-13 | 2019-01-24 | Sage Therapeutics Inc | Esteroides neuroactivos y metodos para su uso. |
| EP3865135A3 (en) | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids for use in therapy |
| WO2015120280A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| BR112017007053A2 (pt) | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| SI3812392T1 (sl) | 2015-07-06 | 2025-09-30 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| MA42410B1 (fr) | 2015-07-06 | 2021-04-30 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| HUE059491T2 (hu) | 2016-04-01 | 2022-11-28 | Sage Therapeutics Inc | Oxiszterolok és azok alkalmazási eljárásai |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3481846T (pt) | 2016-07-07 | 2021-08-13 | Sage Therapeutics Inc | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda |
| WO2018013615A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46566A (fr) | 2016-10-18 | 2019-08-28 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| JP7224307B2 (ja) | 2017-06-23 | 2023-02-17 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁酸誘導体の調製のための方法及び中間体 |
| JP7312169B2 (ja) | 2017-11-10 | 2023-07-20 | マリナス ファーマシューティカルズ インコーポレイテッド | 遺伝性てんかん性障害の処置に使用するガナキソロン |
| TWI855081B (zh) | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
-
2012
- 2012-09-07 EP EP23171488.2A patent/EP4245369A3/en active Pending
- 2012-09-07 CN CN202111105989.9A patent/CN113956315B/zh active Active
- 2012-09-07 CN CN201711063812.0A patent/CN107936076B/zh active Active
- 2012-09-07 HR HRP20230747TT patent/HRP20230747T1/hr unknown
- 2012-09-07 DK DK12766766.5T patent/DK2753632T3/da active
- 2012-09-07 AU AU2012304412A patent/AU2012304412A1/en not_active Abandoned
- 2012-09-07 BR BR112014005373-1A patent/BR112014005373B1/pt active IP Right Grant
- 2012-09-07 SM SM20230232T patent/SMT202300232T1/it unknown
- 2012-09-07 JP JP2014529913A patent/JP6205362B2/ja active Active
- 2012-09-07 US US14/343,603 patent/US20150158903A1/en not_active Abandoned
- 2012-09-07 CN CN201280054927.2A patent/CN103958540B/zh active Active
- 2012-09-07 HU HUE12766766A patent/HUE062616T2/hu unknown
- 2012-09-07 PT PT127667665T patent/PT2753632T/pt unknown
- 2012-09-07 RU RU2014113548A patent/RU2665571C2/ru active
- 2012-09-07 ES ES12766766T patent/ES2951664T3/es active Active
- 2012-09-07 EP EP12766766.5A patent/EP2753632B1/en active Active
- 2012-09-07 FI FIEP12766766.5T patent/FI2753632T3/fi active
- 2012-09-07 LT LTEPPCT/US2012/054261T patent/LT2753632T/lt unknown
- 2012-09-07 WO PCT/US2012/054261 patent/WO2013036835A1/en not_active Ceased
- 2012-09-07 CA CA2848212A patent/CA2848212C/en active Active
- 2012-09-07 PL PL12766766.5T patent/PL2753632T3/pl unknown
- 2012-09-07 CN CN202410996084.2A patent/CN119192267A/zh active Pending
- 2012-09-07 RS RS20230525A patent/RS64332B1/sr unknown
- 2012-09-07 SI SI201232034T patent/SI2753632T1/sl unknown
-
2017
- 2017-06-29 AU AU2017204452A patent/AU2017204452B2/en active Active
- 2017-09-04 JP JP2017169737A patent/JP2018021059A/ja not_active Withdrawn
-
2018
- 2018-08-28 US US16/114,791 patent/US10759828B2/en active Active
-
2019
- 2019-01-25 JP JP2019011169A patent/JP6777773B2/ja active Active
- 2019-09-10 AU AU2019227507A patent/AU2019227507B2/en active Active
-
2020
- 2020-07-29 US US16/942,235 patent/US20210147470A1/en not_active Abandoned
- 2020-10-08 JP JP2020170611A patent/JP2021008504A/ja not_active Withdrawn
-
2021
- 2021-06-21 AU AU2021204183A patent/AU2021204183B2/en active Active
-
2022
- 2022-03-29 US US17/707,303 patent/US12129275B2/en active Active
-
2023
- 2023-01-10 JP JP2023001738A patent/JP7786665B2/ja active Active
- 2023-05-15 AU AU2023203028A patent/AU2023203028B2/en active Active
-
2024
- 2024-09-23 US US18/893,387 patent/US20250257092A1/en active Pending
-
2025
- 2025-04-09 JP JP2025064398A patent/JP2025108535A/ja active Pending
- 2025-05-26 AU AU2025203873A patent/AU2025203873A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526469A5 (enExample) | ||
| RU2014113548A (ru) | Нейроактивные стероиды, композиции и их применения | |
| JP2014528485A5 (enExample) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2017531020A5 (enExample) | ||
| JP2013512926A5 (enExample) | ||
| JP2016513663A5 (enExample) | ||
| JP2015512951A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| JP2018104454A5 (enExample) | ||
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| JP2012530779A5 (enExample) | ||
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| JP2005535592A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| RU2017119222A (ru) | Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения | |
| AR082699A1 (es) | Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto | |
| JP2011132222A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| RU2012101947A (ru) | Способы лечения и профилактики усталости | |
| JP2010538001A5 (enExample) | ||
| JP2019511460A5 (enExample) | ||
| JP2017518323A5 (enExample) | ||
| JP2011530521A5 (enExample) |